"Pelvic radiation disease": new understanding and new solutions for a new disease in the era of cancer survivorship

- Andreyev, H. Jervoise N., Wotherspoon, Andrew, Denham, James W., Hauer-Jensen, Martin

Measuring personal and functional changes in prostate cancer survivors: development and validation of the FADE: data from the TROG 03.04 RADAR trial

- Bitsika, Vicki, Sharpley, Christopher F., Christie, David R. H., Bradford, Rosemary, Steigler, Allison, Denham, James W.

The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer

- Buffart, Laurien M., Newton, Robert U., Chinapaw, Mai J., Taaffe, Dennis R., Spry, Nigel A., Denham, James W., Joseph, David J., Lamb, David S., Brug, Johannes, Galvão, Daniel A.

Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial

- Capp, Anne, Inostroza-Ponta, Mario, Atkinson, Chris, North, John, Poulsen, Michael, Spry, Nigel A., Tai, Keen-Hun, Wynne, Chris, Duchesne, Gillian, Steigler, Allison, Denham, James W., Bill, Dana, Moscato, Pablo, Lai, Chi, Christie, David, Lamb, David, Turner, Sandra, Joseph, David, Matthews, John

Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer

- Chang, David, Joseph, David J., Ebert, Martin A., Galvão, Daniel A., Taaffe, Dennis R., Denham, James W., Newton, Robert U., Spry, Nigel A.

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

- D'Amico, Anthony V., Chen, Ming-Hui, de Castro, Mario, Loffredo, Marian, Lamb, David S., Steigler, Allison, Kantoff, Philip W., Denham, James W.

Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer

- D'Amico, Anthony V., Chen, Ming-Hui, Crook, Juanita, Armstrong, John G., Malone, Shawn, Steigler, Allison, Dunne, Mary, Kantoff, Phillip W., Denham, James W.

Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point

- Delahunt, Brett, Lamb, David S,, Srigley, John R., Murray, Judy D,, Wilcox, Chantelle, Samaratunga, Hemamali, Atkinson, Christopher, Spry, Nigel A., Joseph, David, Denham, James W.

Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy

- Denham, James W., Steigler, Allison

Radiation induced bowel injury: a neglected problem

- Denham, James W., Hauer-Jensen, Martin

The radiotherapeutic injury: a complex 'wound'

- Denham, James W., Hauer-Jensen, Martin

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial

- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Kenny, Lizbeth, Duchesne, Gillian, Delahunt, Brett, McElduff, Patrick, Joseph, David, Spry, Nigel A., Lamb, David S., Tai, Keen-Hun, Matthews, John, Atkinson, Chris, Turner, Sandra, Christie, David

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Wynne, Chris, D'Este, Catherine, Lamb, David S., Joseph, David, Turner, Sandra, Matthews, John, Atkinson, Chris, North, John, Christie, David, Spry, Nigel A.

When to choose radiotherapy for prostate cancer, and what technique?

- Denham, James W.

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

- Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials

- Denham, James W., Bender, Ron, Paradice, William E. J.

PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer?

- Denham, James W., Lamb, David S., Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, D'Este, Catherine

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Gogna, Nirdosh Kumar, Gill, Suki, Tan, Hendrick, Kearvell, Rachel, Murray, Judy, Ebert, Martin, Haworth, Annette, Kennedy, Angel, Delahunt, Brett, Joseph, David, Oldmeadow, Christopher, Holliday, Elizabeth G., Attia, John, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizbeth

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer

- Denham, James W., Kumar, Mahesh, Turner, Sandra, Greer, Peter B., D'Este, Catherine, Steigler, Allison, Gleeson, Paul S., Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

- Denham, James W., Steigler, Allison, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Tai, Keen-Hun, Spry, Nigel A., Gleeson, Paul S., D'Este, Catherine